OakChart

ProQR Therapeutics N.V

PRQRHealthcare·Biotechnology·Netherlands·Micro·NASD·Nov 11 • 3:59 PM ET

1.26-0.05 (-3.82%)
2026-11-11 22:57 CET
Market cap
184.87 USD m
Revenue, TTM
21.39 USD m
Net income, TTM
-49.05 USD m
Free cash flow, TTM
-59.19 USD m
EPS diluted, TTM
-0.46
P/E
-
Compare

Price

PRQR against its 20, 50 and 200-day averages
2050200beatearnings
1.502.002.505.1M10.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PRQRclose 1.2620-day 1.3550-day 1.60200-day 1.681.2652w high

49.3% under the 52-week high of 2.49 on 16 Dec 2025. 52-week low 1.20 on 27 Oct 2026. Last 15 sessions, 25.0% high to low

Volume 0.43× normal · the line is the 50-bar volume average

Profile

PRQR
52-week range, 5% of the way up
1.202.48

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

IPOSep 18, 2014
Beta0.28
ATR, 14d0.09
Rel volume0.43
Short float2.88%
Insider own28.85%
Inst own52.07%

Snapshot

6 groups

Valuation

Index-
Market Cap177.81M
Enterprise Value58.98M
Income-49.05M
Sales21.39M
Book/sh0.64
Cash/sh0.95
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOSep 18, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S8.31
P/B1.96
P/C1.33
P/FCF-
EV/EBITDA-
EV/Sales2.76
Quick Ratio3.49
Current Ratio3.49
Debt/Eq0.17
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.46
EPS next Y-0.55
EPS next Q-0.11
EPS this Y-6.21%
EPS next Y-16.25%
EPS next 5Y11.24%
EPS past 3/5Y21.80% 15.68%
Sales past 3/5Y68.13% -
EPS Y/Y TTM-4.53%
Sales Y/Y TTM19.49%
EPS Q/Q29.54%
Sales Q/Q135.40%
EarningsAug 13 BMO
EPS/Sales Surpr.28.97% 122.24%

Ownership

Insider Own28.85%
Insider Trans2.00%
Inst Own52.07%
Inst Trans20.57%
ROA-31.23%
ROE-57.88%
ROIC-48.66%
Gross Margin85.00%
Oper. Margin-234.12%
Profit Margin-229.34%
SMA20-6.63%
SMA50-21.43%
SMA200-24.93%
Trades-

Technical

Shs Outstand141.12M
Shs Float100.41M
Short Float2.88%
Short Ratio3.52
Short Interest2.89M
52W High2.48 -49.30%
52W Low1.20 5.00%
Volatility6.12% 7.25%
ATR (14)0.09
RSI (14)36.73
Beta0.28
Rel Volume0.43
Avg Volume819.57K
Volume352,691

Performance

Perf Week-10.64%
Perf Month-14.86%
Perf Quarter-31.89%
Perf Half Y-25.88%
Perf YTD-37.62%
Perf Year-41.67%
Perf 3Y-7.35%
Perf 5Y-83.91%
Perf 10Y-73.75%
Recom1.00
Target Price8.46
Prev Close1.31
Price1.26
Change %-3.82%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 20, 2026InitiatedBBofA SecuritiesBuy$8+534.9%
Mar 12, 2026ResumedOOppenheimerOutperform$9+614.3%
Apr 29, 2025ResumedCCantor FitzgeraldOverweight$8+534.9%
Apr 29, 2025InitiatedEEvercore ISIOutperform$5+296.8%
Mar 10, 2025UpgradeCCitigroupNeutral → Buy$4+217.5%
Jan 10, 2025InitiatedOOppenheimerOutperform$15+1,090.5%
Oct 29, 2024UpgradeRRaymond JamesOutperform → Strong Buy$6 → $14+1,011.1%
Nov 08, 2023UpgradeCChardan Capital MarketsNeutral → Buy$2+58.7%
Mar 30, 2023UpgradeJJMP SecuritiesMkt Perform → Mkt Outperform$1.50 → $5+296.8%
Dec 22, 2022UpgradeCCantor FitzgeraldNeutral → Overweight$0.80 → $5+296.8%

Peers

Mkt cap
TickerCompanyMkt cap
KRROKorro Bio Inc197.78M
WVEWave Life Sciences Inc674.52M
ADRXADARx Pharmaceuticals Inc1.47B
SLNSilence Therapeutics Plc ADR1.23B
PRMEPrime Medicine Inc779.92M
STOKStoke Therapeutics Inc1.82B
BEAMBeam Therapeutics Inc2.67B
ARWRArrowhead Pharmaceuticals Inc6.97B
IONSIonis Pharmaceuticals Inc4.72B
MIRMMirum Pharmaceuticals Inc6.18B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
de Boer Daniel AntonChief Executive OfficerJul 31 '26Buy1.77200,000353,960500,000Aug 03 04:01 PM
Filius BartDirectorJul 17 '26Buy1.72150,000257,925300,000Jul 21 08:00 AM
de Boer Daniel AntonChief Executive OfficerJul 09 '26Buy1.74150,000261,000300,000Jul 13 08:00 AM
de Boer Daniel AntonChief Executive OfficerJul 07 '26Buy1.59150,000238,500150,000Jul 08 02:55 PM
Filius BartDirectorJun 26 '26Buy1.54150,000231,000150,000Jun 30 04:01 PM

News

latest 14 of 200
  • ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences (GlobeNewswire) +5.22%
  • ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor (GlobeNewswire) -10.53%
  • ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 (GlobeNewswire)
  • ProQR to Participate in Upcoming Investor Conferences in September 2026 (GlobeNewswire)
  • ProQR: Q2 Earnings Snapshot (Associated Press)
  • ProQR Announces Second Quarter 2026 Operating and Financial Results (GlobeNewswire)
  • ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -13.54%
  • ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform (GlobeNewswire)
  • ProQR Announces First Quarter 2026 Operating and Financial Results (GlobeNewswire)
  • ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer RNA Editing Platform (GlobeNewswire)
  • ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 (GlobeNewswire) +5.81%
  • ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors (GlobeNewswire)
  • ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event (GlobeNewswire) +7.65% +8.20%
  • ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.092-0.130-0.08910.104.547
2026Q12026-05-12-0.153-0.140-0.1492.395.257
2025Q42026-03-12-0.104-0.103-0.1015.496.557
2025Q32025-11-06-0.115-0.116-0.1223.315.817
2025Q22025-08-07-0.140-0.141-0.1314.454.481
2025Q12025-05-08-0.113-0.100-0.1015.116.007
2024Q42025-03-13-0.100-0.097-0.1034.875.237
2024Q32024-11-07-0.107-0.115-0.1094.1211.985
2024Q22024-08-08-0.033-0.136-0.0366.8912.515
2024Q12024-05-09-0.097-0.118-0.1024.782.786
2023Q42024-03-13-0.0850.019-0.0756.1517.266
2023Q32023-11-07-0.075-0.091-0.0771.474.897
2023Q22023-08-03-0.110-0.122-0.1081.321.357
2023Q12023-05-16-0.120-0.128-0.1190.711.446
2022Q42023-03-29-0.187-0.195-0.1501.171.027
2022Q32022-11-09-0.341-0.209-0.3440.960.837

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.499-1.476-1.5402.022.19
2020FY-1.137-1.114-1.06011.3811.29
2021FY-1.067-1.018-1.1351.502.91
2022FY-0.998-0.993-0.9455.1823.77
2023FY-0.403-0.301-0.3759.7619.55
2024FY-0.361-0.349-0.34921.2718.14
2025FY-0.459-0.472-0.46518.3918.87
2026FY--0.474--18.84
2027FY--0.551--21.92
2028FY--0.312--55.41
2029FY--0.473--62.36
2030FY--0.067--172.81

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-277104.240.005.59
2026Q3S2026-09-307134.310.005.67
2026Q3S2026-09-297044.300.005.69
2026Q3S2026-09-097044.400.005.81
2026Q3S2026-08-208043.870.005.84
2026Q3S2026-08-147044.370.005.77
2026Q3S2026-08-137134.380.005.76
2026Q3S2026-07-267104.540.006.03
2026Q3S2026-06-267214.540.006.02
2026Q3S2026-06-247114.520.006.03
2026Q3S2026-06-227114.560.006.08
2026Q3S2026-05-127124.690.006.24
2026Q3S2026-04-247214.850.005.84
2026Q3S2026-04-086214.680.005.84

Estimate history

EPS, annual-1.94-1.278-1.54-1.06-1.135-0.945-0.375-0.349-0.452-0.4638
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.036-0.109-0.103-0.101-0.131-0.122-0.101-0.149-0.092
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00001.63.7777.04220.44917.95121.39
Period201720182019202020212022202320242025TTM
Sales, quarterly6.7884.2224.5944.7564.3263.3685.4572.37810.184
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual31.92243.1549.74650.20567.71677.38778.461102.714103.011141.121
Period201720182019202020212022202320242025MRQ
Shares, quarterly81.6881.683102.714105.343105.344105.345103.011105.363141.121
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue21.3917.9520.457.043.781.600.000.000.00
Cost of Goods Sold Incl. D&A3.213.052.99-2.65-2.682.301.12
Gross Profit18.1814.9017.46-1.59--2.68-2.30-1.12
Selling, General and Administrative Excl. Other68.2564.4351.1242.0270.4167.6856.3964.1648.49
Research and Development53.0747.8436.8025.0351.2749.9041.4350.2634.55
Other Operating Expense0.000.000.000.000.000.000.000.00-
Operating Income-50.07-49.53-33.65-37.70-69.28-68.83-59.07-66.46-49.61
Interest Expense-1.021.081.274.963.612.181.210.96
Unusual Expense-0.09-0.27-0.37-3.05-1.392.220.10--
Net Income Before Taxes-49.02-47.59-30.24-30.07-67.37-72.51-52.63-63.85-43.75
Income Taxes0.030.02-0.21-0.080.100.140.140.150.00
Consolidated Net Income-49.05-47.61-30.03-29.98-67.48-72.90-53.14-63.51-43.75
Net Income From Continuing Operations-49.05-47.61-30.03-30.40-67.71-72.83-53.08-63.22-43.53
Net Income-49.05-47.61-30.03-30.40-67.71-72.83-53.08-63.22-43.53
EPS (Recurring)-0.45-0.45-0.35-0.40-0.96-1.11-1.06-1.54-1.28
EPS (Basic, Before Extraordinaries)-0.46-0.45-0.35-0.38-0.95-1.13-1.06-1.54-1.28
EPS (Diluted)-0.46-0.45-0.35-0.38-0.95-1.13-1.06-1.54-1.28
EBITDA-46.86-46.48-30.67-34.98-66.63-66.08-56.39-64.16-48.49
Non-Operating Income (Expense)0.962.704.125.855.492.158.723.836.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.273.362.042.522.265.516.704.993.80
Price To Sales Ratio9.5611.8511.1622.7870.18321.23---
Gross Margin85.0083.0185.40-42.18----
Operating Margin-234.12-275.91-164.57-535.31-1,834.28-4,300.89---
Net Margin-229.34-265.21-146.86-431.67-1,792.54-4,551.03---
Shares Outstanding141.12103.01102.7178.4677.3967.7250.2049.7543.15
Market Capitalization184.87184.87273.49160.02263.78513.05210.60489.23594.67

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue10.182.385.463.374.334.764.594.22
Cost of Goods Sold Incl. D&A0.820.810.790.780.770.710.720.76
Gross Profit9.361.574.672.583.564.043.883.47
Selling, General and Administrative Excl. Other19.6217.5315.2915.8117.6215.6614.7813.19
Research and Development14.7313.8411.5512.9512.9312.9711.3210.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.26-15.97-10.62-13.23-14.06-11.62-10.90-9.73
Unusual Expense0.04-0.06-0.070.000.12-0.30-0.08-0.15
Net Income Before Taxes-10.12-15.66-10.38-12.86-13.78-10.61-9.93-8.91
Income Taxes0.030.000.000.000.020.000.000.00
Consolidated Net Income-10.15-15.66-10.38-12.86-13.80-10.61-9.93-8.91
Net Income From Continuing Operations-10.15-15.66-10.38-12.86-13.80-10.61-9.93-8.91
Net Income-10.15-15.66-10.38-12.86-13.80-10.61-9.93-8.91
EPS (Recurring)-0.09-0.15-0.10-0.12-0.13-0.10-0.10-0.11
EPS (Basic, Before Extraordinaries)-0.09-0.15-0.10-0.12-0.13-0.10-0.10-0.11
EPS (Diluted)-0.09-0.15-0.10-0.12-0.13-0.10-0.10-0.11
EBITDA-9.44-15.16-9.83-12.44-13.30-10.90-10.18-8.97
Non-Operating Income (Expense)0.180.250.170.370.400.710.890.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.001.241.060.970.760.590.450.50
Price To Sales Ratio9.5610.9911.6213.1612.016.8812.527.67
Gross Margin91.9365.8685.5276.7282.3285.0084.4282.10
Operating Margin-100.72-671.37-194.65-392.68-325.05-244.26-237.22-230.39
Net Margin-99.65-658.29-190.27-381.89-319.07-223.04-216.04-210.98
Shares Outstanding141.12105.36103.01105.35105.34105.34102.7181.68
Market Capitalization184.87170.68212.53224.10214.63139.93273.49148.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments108.53154.71131.37101.15213.2592.79125.66120.6957.76
Short Term Receivables5.972.101.4061.090.940.981.342.450.56
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.092.500.882.613.574.141.710.742.39
Total Current Assets117.59159.31133.65164.85217.7597.91128.71123.8860.71
Net Property, Plant & Equipment14.8314.6118.6717.3319.8622.762.742.133.01
Total Investments and Advances0.000.000.000.660.720.130.480.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.05
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets132.43173.92152.31182.84238.33120.80131.93126.0163.77
Short Term Debt Incl. Current Port. of LT Debt5.224.621.784.157.172.930.960.002.35
Accounts Payable0.350.021.700.420.220.270.500.150.66
Income Tax Payable-----0.000.070.00-
Other Current Liabilities32.5335.6434.3017.8323.999.4010.819.177.19
Total Current Liabilities38.1040.2837.7822.4031.3812.6012.349.3310.20
Long Term Debt11.2111.4620.0219.3061.4839.0114.278.046.35
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities25.1330.4748.7969.9816.700.000.002.690.00
Total Liabilities74.4482.22106.59111.68109.5751.6126.6120.0616.54
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity57.9991.7045.7271.58129.4569.85105.88106.2247.27
Total Shareholders Equity57.9991.7045.7271.58129.4569.85105.88106.2247.27
Accumulated Minority Interest0.000.000.00-0.41-0.69-0.67-0.56-0.26-0.05
Total Equity57.9991.7045.7271.17128.7669.19105.33105.9547.22
Total Liabilities & Stockholders Equity132.43173.92152.31182.84238.33120.80131.93126.0163.77
Book Value Per Share0.560.890.580.921.911.392.132.461.48
Tangible Book Value Per Share0.560.890.580.921.911.392.132.461.48
Full-Time Employees186.60166.10156.60130.20181.60150.40154.40118.80130.20
Price to Book Ratio2.037.763.284.364.193.024.666.412.02
Return on Assets-31.08-18.41-18.14-32.15-40.56-42.01-49.01-45.87-74.07
Return on Equity-63.61-43.71-52.58-67.36-73.09-60.41-59.61-56.72-95.28
Return on Invested Capital-68.80-29.11-46.24-74.51-38.15-48.76-52.61-38.09-91.81
Quick Ratio3.093.953.547.366.947.7710.4313.285.95
Current Ratio3.093.953.547.366.947.7710.4313.285.95

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-49.58-47.61-30.03-29.98-67.48-72.90-53.14-63.51-43.75
Depreciation3.243.052.992.722.652.752.682.301.12
Other Funds (Non Cash)6.384.642.03-2.36-1.939.862.6610.017.49
Funds from Operations-39.96-39.92-25.02-29.63-66.75-60.29-47.79-51.21-35.14
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-17.88-19.66-14.3552.93-5.2529.54-5.852.001.53
Cash from Operating Activities-57.84-59.58-39.3723.30-72.00-30.75-53.65-49.21-33.61
Capital Expenditures-1.35-1.15-4.41-4.02-0.74-0.57-1.05-0.65-0.37
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.060.010.070.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.00-18.390.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.0018.390.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.008.580.000.000.000.000.00
Cash from Investing Activities-1.35-1.15-4.414.63-0.74-0.50-1.05-0.65-0.37
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock57.210.0877.730.3814.88130.010.8454.56100.35
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock57.210.0877.730.3814.88130.010.8454.56100.35
Proceedsfrom Stock Options57.210.0077.490.0014.84128.220.0054.3499.32
Issuance or Reduction of Debt, Net0.000.000.00-1.09-45.5832.6916.383.041.65
Change in Long Term Debt-0.00--1.09-45.5832.6916.383.040.00
Issuance of Long Term Debt-0.00-0.000.0032.6916.383.040.00
Reduction of Long Term Debt-0.00--1.09-45.580.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities54.89-2.0776.02-2.46-32.46161.7316.5356.19102.00
Exchange Rate Effect0.29-1.520.730.657.731.53-3.000.81-0.20
Net Change in Cash-4.01-64.3232.9726.11-97.48132.01-41.177.1367.81
Free Cash Flow-59.19-60.73-40.9021.81-72.74-31.32-54.70-49.86-33.98
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---7.35-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments133.9193.43108.53125.59140.59143.03
Short Term Receivables2.133.135.972.992.852.98
Inventories0.000.000.000.000.000.00
Other Current Assets3.023.663.092.242.453.14
Total Current Assets139.06100.22117.59130.81145.88149.16
Net Property, Plant & Equipment13.6313.8914.8315.3015.5614.70
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets152.69114.11132.43146.11161.45163.85
Short Term Debt Incl. Current Port. of LT Debt5.155.325.225.375.344.71
Accounts Payable0.000.220.350.361.510.45
Other Current Liabilities34.7234.8632.5333.2031.9931.27
Total Current Liabilities39.8740.3938.1038.9338.8436.42
Long Term Debt9.9410.4511.2111.7712.3011.60
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities12.0219.9425.1328.3531.6830.57
Total Liabilities61.8370.7974.4479.0582.8278.59
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity90.8743.3257.9967.0678.6385.27
Total Shareholders Equity90.8743.3257.9967.0678.6385.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity90.8743.3257.9967.0678.6385.27
Total Liabilities & Stockholders Equity152.69114.11132.43146.11161.45163.85
Book Value Per Share0.640.410.560.640.750.81
Tangible Book Value Per Share0.640.410.560.640.750.81
Full-Time Employees--186.60---
Price to Book Ratio2.032.883.172.852.521.49
Return on Assets-31.23-37.92-31.11-35.57-30.03-21.73
Return on Equity-57.88-81.98-63.67-99.43-75.97-52.64
Return on Invested Capital-10.07-29.12-15.00-16.32-15.18-10.95
Quick Ratio3.492.483.093.363.764.10
Current Ratio3.492.483.093.363.764.10

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-10.05-15.66-10.23-13.64-14.62-10.61
Depreciation0.820.810.780.830.820.71
Other Funds (Non Cash)1.741.681.531.431.480.34
Funds from Operations-7.49-13.17-7.91-11.38-12.32-9.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.690.13-7.45-3.87-1.88-7.07
Cash from Operating Activities-14.19-13.04-15.36-15.25-14.20-16.63
Capital Expenditures-0.34-0.19-0.61-0.21-0.13-0.24
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.34-0.19-0.61-0.21-0.13-0.24
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock57.210.000.000.000.010.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock57.210.000.000.000.010.07
Proceedsfrom Stock Options57.210.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt-0.00---0.00
Issuance of Long Term Debt-0.00---0.00
Reduction of Long Term Debt-0.00---0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities56.49-0.36-0.69-0.55-0.37-0.53
Exchange Rate Effect0.020.340.02-0.09-1.01-0.50
Net Change in Cash41.98-13.25-16.64-16.10-15.71-17.89
Free Cash Flow-14.52-13.23-15.97-15.46-14.33-16.86

Revenue breakdown

Equity consideration2024: 536.65K
Milestone payments2024: 3.06M
Total Pharmaceutical Preparations revenue2025: 17.94M
Up-front payments2024: 16.86M
Netherlands2024: 20.45M 2025: 17.94M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.88%2.9M100.4M858.37K
2026-10-152.90%2.9M100.4M822.95K
2026-09-302.92%2.9M98.3M876.33K
2026-09-152.45%2.4M98.3M1.11M
2026-08-312.50%2.5M98.3M1.10M
2026-08-142.26%2.2M98.3M998.63K
2026-07-312.58%2.2M86.1M959.50K
2026-07-152.48%2.3M93.0M981.86K
2026-06-301.33%1.2M90.0M884.44K
2026-06-151.41%1.0M71.4M619.32K
2026-05-291.24%0.9M71.4M584.47K
2026-05-151.21%0.9M71.4M542.88K
2026-04-301.18%0.8M71.4M528.04K
2026-04-151.77%1.3M71.4M442.23K
2026-03-312.36%1.7M70.6M417.83K
2026-03-132.38%1.7M70.6M437.73K
2026-02-272.41%1.7M70.6M506.01K
2026-02-132.52%1.8M70.6M516.29K
2026-01-302.59%1.8M69.1M511.40K
2026-01-151.73%1.2M70.1M540.51K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.251.250.000.0000.000.000.932-0.0080.000
call1.000.001.000.0016.9330.000.000.810-0.0060.001
call1.500.000.150.052.97085.0010.000.443-0.0130.001
call2.000.000.150.243.85736.000.000.362-0.0160.001
call2.500.001.000.055.18089.000.000.328-0.0210.001
call5.000.001.000.005.4100.000.000.125-0.0130.000
call7.500.000.050.016.44710.000.000.113-0.0140.000
put0.500.001.000.005.6900.000.00-0.067-0.0080.000
put1.000.000.050.102.9893.000.00-0.227-0.0100.001
put1.500.000.950.1510.81661.000.00-0.557-0.0130.001
put2.000.251.250.508.36051.000.00-0.638-0.0180.001
put2.500.801.800.009.2570.000.00-0.672-0.0200.001
put5.003.304.300.0010.3720.000.00-0.728-0.0270.001
put7.503.708.500.000.0000.000.00-0.886-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-306-K/A2026-10-30SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-23SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-29SCHEDULE 13GSEC
2026-07-29SCHEDULE 13D/ASEC
2026-07-24SCHEDULE 13G/ASEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-15EFFECTEffectiveness filing by commission orderSEC
2026-07-15424B5SEC
2026-07-15SCHEDULE 13G/ASEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-06F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-06-30SCHEDULE 13D/ASEC
2026-06-304/A2026-06-02SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-26SEC
2026-06-26424B5SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-03SCHEDULE 13D/ASEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-06-023Initial statement of beneficial ownership of securities2026-06-02SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC
2026-05-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-071.11M400
2026-06231.00K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ADAGE CAPITAL PARTNERS GP, L.L.C.8.56%
Aberdeen Group plc7.00%
Affinity Asset Advisors, LLC5.26%
Privium Fund Management B.V.3.96%
Ikarian Capital, LLC3.25%
Woodline Partners LP3.11%
HEIGHTS CAPITAL MANAGEMENT, INC2.62%
MORGAN STANLEY1.68%
SPHERA FUNDS MANAGEMENT LTD.1.67%
Kynam Capital Management, LP1.49%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND401.77%
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND392.83%
LVIP Mondrian Global Income Fund40.05%
Fidelity Series International Developed Markets Bond Index Fund23.35%
Loomis Sayles Global Allocation Fund18.76%
SIT International Fixed Income Fund14.02%
abrdn World Healthcare Fund5.99%
State Street(R) SPDR(R) Bloomberg International Treasury Bond ETF5.83%
Loomis Sayles Global Allocation Portfolio5.55%
iShares Global Government Bond USD Hedged Active ETF4.05%

OakChart. PRQR. Cached 15 minutes.